The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy

Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/...

Descripción completa

Detalles Bibliográficos
Autores principales: Brusamolino, Ercole, Gotti, Manuel, Fiaccadori, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2012
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375741/
https://www.ncbi.nlm.nih.gov/pubmed/22708037
http://dx.doi.org/10.4084/MJHID.2012.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375741/
https://www.ncbi.nlm.nih.gov/pubmed/22708037
http://dx.doi.org/10.4084/MJHID.2012.022

Ejemplares similares